caa a22 4500 463256077 CHVBK 20180405153355.0 cr unu---uuuuu 170326e20070301xx s 000 0 eng 10.1007/s00277-006-0220-3 doi (NATIONALLICENCE)springer-10.1007/s00277-006-0220-3 Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin [Elektronische Daten] [Suzanne Biehn, Dominic Moore, Peter Voorhees, Reynaldo Garcia, Mary Lehman, E. Dees, Robert Orlowski] A phase I study of a combination of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin showed significant anti-tumor activity against advanced multiple myeloma, with 36% of patients achieving a complete or near-complete response and 73% having a partial response or better. Given this encouraging efficacy, it was therefore of interest to update the prior experience and define parameters such as time to progression, time to retreatment, and overall survival. Additional follow-up was collected on all evaluable multiple myeloma patients and revealed a median time to progression of 9.3months versus 3.8months on whatever had been the patient's prior therapy. Time to retreatment was prolonged from 5.9months after the patient's prior therapy to 24.2months after bortezomib with pegylated liposomal doxorubicin. The median overall survival after therapy with bortezomib and pegylated liposomal doxorubicin was 38.3months. These findings compare favorably with results reported for bortezomib alone and support the possibility that the bortezomib/pegylated liposomal doxorubicin regimen may provide superior efficacy against relapsed/refractory multiple myeloma. Springer-Verlag, 2006 Bortezomib nationallicence Liposomal doxorubicin nationallicence Multiple myeloma nationallicence Phase I trial nationallicence Proteasome inhibitor nationallicence Biehn Suzanne University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA aut Moore Dominic Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA aut Voorhees Peter Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB # 7295, Mason Farm Road, 27599-7295, Chapel Hill, NC, USA aut Garcia Reynaldo Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB # 7295, Mason Farm Road, 27599-7295, Chapel Hill, NC, USA aut Lehman Mary Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB # 7295, Mason Farm Road, 27599-7295, Chapel Hill, NC, USA aut Dees E. University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA aut Orlowski Robert University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA aut Annals of Hematology Springer-Verlag 86/3(2007-03-01), 211-216 0939-5555 86:3<211 2007 86 277 https://doi.org/10.1007/s00277-006-0220-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00277-006-0220-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Biehn Suzanne University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Moore Dominic Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Voorhees Peter Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB # 7295, Mason Farm Road, 27599-7295, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Garcia Reynaldo Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB # 7295, Mason Farm Road, 27599-7295, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Lehman Mary Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB # 7295, Mason Farm Road, 27599-7295, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Dees E. University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Orlowski Robert University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA aut NATIONALLICENCE 773 0- Annals of Hematology Springer-Verlag 86/3(2007-03-01), 211-216 0939-5555 86:3<211 2007 86 277 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer